Oxis Biotech Gains Key Patent Ruling For Its Cancer Drug, OXS-1550

LOS ANGELES, Feb. 23, 2016 /PRNewswire/ Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA] announced today that inventors of OXS-1550 received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of various human cancers. We are pleased the USPTO has agreed that OXS-1550 is a patentable therapeutic composition. This is a significant milestone for Oxis and will attribute meaningful value to our existing IP portfolio, said Anthony J. Cataldo, Chairman and Chief Executive Officer of Oxis Biotech. Dr. Daniel Vallera, the inventor of OXS-1550 and Director of the Section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center, said he believes OXS-1550 will play an important role in the treatment of cancer. The drug is designed to identify certain cancer cells and


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: